Literature DB >> 23620396

The impact of membrane permeability and dialysate purity on cardiovascular outcomes.

Gulay Asci1, Huseyin Tz, Mehmet Ozkahya, Soner Duman, Meltem Sezis Demirci, Mustafa Cirit, Savas Sipahi, Hamad Dheir, Devrim Bozkurt, Fatih Kircelli, Ebru Sevinc Ok, Sinan Erten, Muhittin Ertilav, Timur Kose, Ali Basci, Jochen G Raimann, Nathan W Levin, Ercan Ok.   

Abstract

The effects of high-flux dialysis and ultrapure dialysate on survival of hemodialysis patients are incompletely understood. We conducted a randomized controlled trial to investigate the effects of both membrane permeability and dialysate purity on cardiovascular outcomes. We randomly assigned 704 patients on three times per week hemodialysis to either high- or low-flux dialyzers and either ultrapure or standard dialysate using a two-by-two factorial design. The primary outcome was a composite of fatal and nonfatal cardiovascular events during a minimum 3 years follow-up. We did not detect statistically significant differences in the primary outcome between high- and low-flux (HR=0.73, 95% CI=0.49 to 1.08, P=0.12) and between ultrapure and standard dialysate (HR=0.90, 95% CI=0.61 to 1.32, P=0.60). Posthoc analyses suggested that cardiovascular event-free survival was significantly better in the high-flux group compared with the low-flux group for the subgroup with arteriovenous fistulas, which constituted 82% of the study population (adjusted HR=0.61, 95% CI=0.38 to 0.97, P=0.03). Furthermore, high-flux dialysis associated with a lower risk for cardiovascular events among diabetic subjects (adjusted HR=0.49, 95% CI=0.25 to 0.94, P=0.03), and ultrapure dialysate associated with a lower risk for cardiovascular events among subjects with more than 3 years of dialysis (adjusted HR=0.55, 95% CI=0.31 to 0.97, P=0.04). In conclusion, this trial did not detect a difference in cardiovascular event-free survival between flux and dialysate groups. Posthoc analyses suggest that high-flux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and that ultrapure dialysate may benefit patients with longer dialysis vintage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23620396      PMCID: PMC3665396          DOI: 10.1681/ASN.2012090908

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  20 in total

1.  Mechanisms for the formation of glycoxidation products in end-stage renal disease.

Authors:  M F Weiss; P Erhard; F A Kader-Attia; Y C Wu; P B Deoreo; A Araki; M A Glomb; V M Monnier
Journal:  Kidney Int       Date:  2000-06       Impact factor: 10.612

Review 2.  Hemodiafiltration: clinical evidence and remaining questions.

Authors:  Peter J Blankestijn; Ingrid Ledebo; Bernard Canaud
Journal:  Kidney Int       Date:  2010-02-03       Impact factor: 10.612

3.  Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study.

Authors:  F K Port; R A Wolfe; T E Hulbert-Shearon; J T Daugirdas; L Y Agodoa; C Jones; S M Orzol; P J Held
Journal:  Am J Kidney Dis       Date:  2001-02       Impact factor: 8.860

4.  Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters.

Authors:  H Schiffl; S M Lang; D Stratakis; R Fischer
Journal:  Nephrol Dial Transplant       Date:  2001-09       Impact factor: 5.992

5.  Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.

Authors:  T Sitter; A Bergner; H Schiffl
Journal:  Nephrol Dial Transplant       Date:  2000-08       Impact factor: 5.992

6.  Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.

Authors:  Vera Krane; Detlef H Krieter; Manfred Olschewski; Winfried März; Johannes F E Mann; Eberhard Ritz; Christoph Wanner
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

7.  Effect of membrane permeability on survival of hemodialysis patients.

Authors:  Francesco Locatelli; Alejandro Martin-Malo; Thierry Hannedouche; Alfredo Loureiro; Menelaos Papadimitriou; Volker Wizemann; Stefan H Jacobson; Stanislaw Czekalski; Claudio Ronco; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

8.  Effect of dialysis dose and membrane flux in maintenance hemodialysis.

Authors:  Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation.

Authors:  S R Lederer; H Schiffl
Journal:  Nephron       Date:  2002-07       Impact factor: 2.847

10.  Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.

Authors:  Alfred K Cheung; Tom Greene; John K Leypoldt; Guofen Yan; Michael Allon; James Delmez; Andrew S Levey; Nathan W Levin; Michael V Rocco; Gerald Schulman; Garabed Eknoyan
Journal:  Clin J Am Soc Nephrol       Date:  2007-12-05       Impact factor: 8.237

View more
  14 in total

1.  Dialysis: Membrane flux, dialysate purity and cardiovascular outcomes.

Authors:  Muriel Grooteman; Menso Nubé
Journal:  Nat Rev Nephrol       Date:  2013-06-25       Impact factor: 28.314

2.  Impedance ratio: a novel marker and a powerful predictor of mortality in hemodialysis patients.

Authors:  C Demirci; G Aşcı; M S Demirci; M Özkahya; H Töz; S Duman; S Sipahi; S Erten; M Tanrısev; E Ok
Journal:  Int Urol Nephrol       Date:  2016-04-19       Impact factor: 2.370

3.  FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.

Authors:  Mehmet Nuri Turan; Fatih Kircelli; Mustafa Yaprak; Ali Riza Sisman; Ozkan Gungor; Selen Bayraktaroglu; Mehmet Ozkahya; Gulay Asci; Jurgen Floege; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2016-02-10       Impact factor: 2.370

Review 4.  Flummoxed by flux: the indeterminate principles of haemodialysis.

Authors:  Sudhir K Bowry; Fatih Kircelli; Madhukar Misra
Journal:  Clin Kidney J       Date:  2021-12-27

5.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

Review 6.  Does delivering more dialysis improve clinical outcomes? What randomized controlled trials have shown.

Authors:  Javier Deira; Mariana Murea; Kamyar Kalantar-Zadeh; Francesco Gaetano Casino; Carlo Basile
Journal:  J Nephrol       Date:  2022-01-18       Impact factor: 4.393

Review 7.  Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease.

Authors:  X Li; H Xu; X C Xiao; S L Deng; W Wang; R Tang
Journal:  Braz J Med Biol Res       Date:  2015-11-27       Impact factor: 2.590

Review 8.  Informed decision-making in delivery of dialysis: combining clinical outcomes with sustainability.

Authors:  Christian Apel; Carsten Hornig; Frank W Maddux; Terry Ketchersid; Julianna Yeung; Adrian Guinsburg
Journal:  Clin Kidney J       Date:  2021-12-27

9.  Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST).

Authors:  Neelke C van der Weerd; Claire H Den Hoedt; Peter J Blankestijn; Michiel L Bots; Marinus A van den Dorpel; Renée Lévesque; Albert H A Mazairac; Menso J Nubé; E Lars Penne; Pieter M ter Wee; Muriel P C Grooteman
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Survival with low- and high-flux dialysis.

Authors:  Emilio Sánchez-Álvarez; Minerva Rodríguez-García; Francesco Locatelli; Carmine Zoccali; Alejandro Martín-Malo; Jürgen Floege; Markus Ketteler; Gerard London; José L Górriz; Boleslaw Rutkowski; Anibal Ferreira; Drasko Pavlovic; Jorge B Cannata-Andía; José L Fernández-Martín
Journal:  Clin Kidney J       Date:  2020-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.